In patients treated with infliximab, do rates of immunogenicity vary based on underlying disease (RA, IBD, sarcoidosis, etc) and/or baseline disease activity?
Are there significant differences in the incidence or timing of antibody development across different diseases?
Community PollStarted
In patients treated with infliximab, how do you approach background DMARD therapy to mitigate immunogenicity?
84 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Rheumatology · Harvard Medical School
Answered on
Yes, rates of infliximab immunogenicity appear to vary based on underlying disease, with evidence showing higher rates for RA than IBD and spondyloarthritis, and tend to increase with higher baseline disease activity. Most patients tend to develop anti-drug antibodies within the first year, but this...
Join for free or sign in to see the full answer